Advanced Pancreatic Cancer

  • IMAGE 1 (Immune Modulation and Gemcitabine Evaluation 1), a Randomised, Open-label Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer designed to provide indicative efficacy results and to assess safety and tolerability
  • 110 patients with advanced pancreatic cancer enrolled
  • 75 randomised to receive gemcitabine and IMM-101, and 35 gemcitabine alone
  • Group treated with IMM-101 had improved survival and slower disease progression with these benefits more pronounced in those patients with metastatic disease at baseline (84% of those enrolled)
  • In this metastatic sub-group an increase of 59% in the median overall survival was observed for the combination therapy compared to gemcitabine alone
  • Encouraging long-term survival was seen in extended analysis of results with the probability of survival for IMM-101 treated metastatic patients (11% at 24 months and 6% at 36 months) comparing favourably with the nab-paclitaxel (Abraxane®, Celgene Corporation)-gemcitabine combination in a similar population of metastatic pancreatic cancer patients
  • IMM-101 well tolerated with 11 patients treated for over 1 year with a maximum duration approaching 4 years

Despite advances in treatment in recent years, advanced pancreatic cancer remains largely incurable with limited treatment options following aggressive chemotherapy regimens and for those not fit enough to receive such chemotherapy as first-line treatment. IMM-101 may be a suitable therapy in these situations and may also be effective as an immunotherapy background for use with first-line chemotherapies other than gemcitabine. Future research will address this. 


Dalgleish AG et al. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. British Journal of Cancer 2016 115:789-796

Dalgleish AG et al. Poster on IMAGE 1 long-term results presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington DC, USA, 17-21 November 2018

Earlier results of the IMAGE 1 trial were presented at the following congresses:

Dalgleish AG et al. Poster presented at the ASCO Gastrointestinal Cancers (GI) Symposium Annual Meeting in San Francisco, USA, 15-17 January 2015

Dalgleish AG et al. Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA, 29 May – 2 June 2015

Dalgleish AG et al. Poster presented at the European Society for Medical Oncology (ESMO) 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain, 1-4 July 2015